Jensen M, Hartmann T, Engvall B, Wang R, Uljon S N, Sennvik K, Näslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L
Karolinska Institutet, NEUROTEC Department, Huddinge, Sweden.
Mol Med. 2000 Apr;6(4):291-302.
The amyloid beta (Abeta) peptide is a key molecule in the pathogenesis of Alzheimer's disease. Reliable methods to detect and quantify soluble forms of this peptide in human biological fluids and in model systems, such as cell cultures and transgenic animals, are of great importance for further understanding the disease mechanisms. In this study, the application of new and highly specific ELISA systems for quantification of Abeta40 and Abeta42 (Abeta peptides ending at residues 40 or 42, respectively) in human cerebrospinal fluid (CSF) are presented.
Monoclonal antibodies WO-2, G2-10 and G2-11 were thoroughly characterized by (SPOT) epitope mapping and immunoprecipitation/mass spectrometry. We determined whether aggregation affected the binding capacities of the antibodies to synthetic peptides and whether components of the CSF affected the ability of the antibodies to bind synthetic Abeta1-40 and Abeta1-42 peptides. The stability of Abeta40 and Abeta42 in CSF during different temperature conditions was also studied to optimize sample handling from lumbar puncture to Abeta assay.
The detection range for the ELISAs were 20-250 pM. The intra-assay variations were 2% and 3%, and the inter-assay variations were 2% and 10% for Abeta40 and Abeta42, respectively. The antibodies specifically detected the expected peptides with equal affinity for soluble and fibrillar forms of the peptide. The presence of CSF obstructed the recognition of synthetic peptides by the antibodies and the immunoreactivity of endogenous CSF Abeta decreased with increasing storage time and temperature.
This study describes highly sensitive ELISAs with thoroughly characterized antibodies for quantification of Abeta40 and Abeta42, an important tool for the understanding of the pathogenesis of Alzheimer's disease. Our results pinpoint some of the difficulties associated with Abeta quantification and emphasize the importance of using a well-documented assay.
β淀粉样蛋白(Aβ)肽是阿尔茨海默病发病机制中的关键分子。在人类生物体液以及细胞培养和转基因动物等模型系统中,检测和定量该肽可溶性形式的可靠方法对于进一步了解疾病机制至关重要。在本研究中,介绍了用于定量人脑脊液(CSF)中Aβ40和Aβ42(分别在第40或42位氨基酸残基处结束的Aβ肽)的新型高特异性酶联免疫吸附测定(ELISA)系统的应用。
通过(SPOT)表位作图以及免疫沉淀/质谱对单克隆抗体WO-2、G2-10和G2-11进行了全面表征。我们确定了聚集是否会影响抗体与合成肽的结合能力,以及脑脊液的成分是否会影响抗体与合成Aβ1-40和Aβ1-42肽的结合能力。还研究了不同温度条件下CSF中Aβ40和Aβ42的稳定性,以优化从腰椎穿刺到Aβ检测的样本处理。
ELISA的检测范围为20 - 250皮摩尔。Aβ40和Aβ42的批内变异分别为2%和3%,批间变异分别为2%和10%。这些抗体能特异性地检测预期的肽,对肽的可溶性和纤维状形式具有同等亲和力。脑脊液的存在阻碍了抗体对合成肽的识别,并且内源性脑脊液Aβ的免疫反应性随储存时间和温度的增加而降低。
本研究描述了用于定量Aβ40和Aβ42的高灵敏度ELISA以及经过全面表征的抗体,这是了解阿尔茨海默病发病机制的重要工具。我们的结果指出了与Aβ定量相关的一些困难,并强调了使用记录完善的检测方法的重要性。